Objective To explore the clinical efficacy and safety of nicorandil in the treatment of chronic ischemic cardiomyopathy patients with heart failure. Methods The chronic ischemic cardiomyopathy patients with heart failure in our hospital were divided into two groups according to the random number table method. Control group underwent conventional anti heart failure treatment and symptomatic supportive treatment , and treatment group was treated by the nicorandil in addition to above treatments. After treatment for 6 months , comparisons of clinical efficacy and safety between two groups were conducted. Results The improvement of heart function in observation group was better than that in control group (Z = -2.302, P = 0.021). After treatment, the LVEF, 6 min walking distance were greater than those before treatment, and the LVESD, LVEDD were less than those before treatment (P < 0.05). The LVEF, 6 min walking distance in observation group after treatment were greater than those in control group and the LVESD , LVEDD were less than those in control group (P < 0.05). The incidence rate of adverse reaction in observation group was 9.59%, and 6.94% in control group, without statistical difference between two groups (χ2 = 0.334,P = 0.563). Conclusion In addition to conventional anti heart failure treatment , nicorandil can significantly improve the curative effect and the heart function in the treatment of chronic ischemic cardiomyopathy patients with heart failure and there are no significant adverse reactions. In addition , patients are tolerant.

Objective To observe the clinical efficacy of different kinds of insulin combined with Metformin in the treatment of T2DM.Methods 120 T2DM patients were selected and divided into three groups according to different therapies of reducing blood sugar with 40 cases in each group.Group A was treated with insulin glargine combined with Metformin;Group B with insulin detemir combined with Metformin and Group C with protamine zinc insulin combined with Metformin .The time for reaching the standards of blood sugar and the corresponding usage amount of insulin of three groups were observed;After 6 months, the three groups were com-pared in terms of FBG, PBG HbA1c, HOMA-IR, TC, TG and LDL-C.Meanwhile, the incidence rate of hypoglycemia after treat-ment was observed.Results Time for reaching the standards of blood sugar in Group A, Group B and Group C was (6.9 ±2.3)d, (4.1 ±3.0)d and (3.8 ±1.5)d, respectively;the corresponding dosages of insulin of the three groups was (19.0 ±7.8)U, (12.1 ±5.9)U and (11.9 ±5.3)U, respectively, with significant difference between Group A and Groups C, D (p<0.05) and insignifi-cant difference between Group B and Group C (p>0.05).After 6 months, FBG, PBG, HbA1c, HOMA-IR in Group B, Group C and Group A were significantly reduced (p<0.05);with insignificance between Group B and Group C (p>0.05).6 months follow-ing the treatment, TC, TG and LDL-C in Group B, Group C and Group A were significantly different (p<0.05), with insignificant difference between Group B and Group C (p<0.05).The incidence rate of hypoglycemia in Group A, Group B and Group C was 22.5%, 20.0% and 5.0%, respectively, with those in Group B and Group C significantly lower than Group A (p<0.05) and in-significant difference between Group B and Group C (p>0.05).Conclusion The insulin detemir and protamine zinc insulin com-bined with Metformin has a better clinical efficacy in the treatment of T2DM.It can promptly control the blood sugar level and lead to a lower incidence rate of hypoglycemia.Therefore it is worthy of promotion.